Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
CD4 lymphopenia
bendamustine
chronic lymphocytic leukaemia
non-Hodgkin lymphoma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
03
08
2018
accepted:
05
11
2018
pubmed:
15
12
2018
medline:
21
3
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-based retrospective analysis of immune reconstitution and risk of infection following BR. Outcomes included timing/correlates of CD4+ recovery and risk of ≥grade 3 infections. Consecutively treated patients (1 April 2014 to 31 January 2017) were included (n = 295),with a median age of 65 years (range 33-92); 57% were 1st line treatments. Median cumulative bendamustine dose was 1080 mg/m
Substances chimiques
Antineoplastic Agents, Alkylating
0
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
957-968Informations de copyright
© 2018 British Society for Haematology and John Wiley & Sons Ltd.